Based upon its initial trial conclusions, American pharmaceutical company, Pfizer, announced it has achieved 90% effective results in the race to develop a safe and efficient vaccine against the ravages of the worldwide coronavirus pandemic.
Experts are applauding the first interim test result tabulations from a large-scale clinical trial which indicated their vaccine could stop the spread of COVID-19 if distribution is approved. Though regulatory endorsement will be needed to begin manufacturing and distribution, it’s unlikely to happen before the end of this year.
The company, who is partnering with German drug-maker BioNTech, stated they have not found any serious or adverse reactions which would warrant safety concerns. US emergency use authorization is currently being sought, offering the possibility of a definitive answer by the end of December.
If approved, the combined effort of the two companies estimates initial production at as many as 50 million doses, which would cover protecting 25 million people. They further project rolling out as many as 1.5 billion doses in the new year.
Ann Sullivan is a contributing staff writer covering national and world news topics. She brings dedicated experience having written international and domestic news, blogs, and web content for over 20 years. She’s also a published poet and graphic designer with degrees in Business and Graphic Communications and has been a music distributor, music industry sponsorship sales director and band manager.